Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumi-NHL: AZD4512 in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20261353Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD4512 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), sponsored by AstraZeneca. Started Oct 2025; status: active.
02
Drugs
AZD4512
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20261353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261353.